366 related articles for article (PubMed ID: 37664750)
1. Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.
He M; Zhang D; Cao Y; Chi C; Zeng Z; Yang X; Yang G; Sharma K; Hu K; Enikeev M
Heliyon; 2023 Aug; 9(8):e19147. PubMed ID: 37664750
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
3. Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.
Adachi K; Tamada K
Cancer Sci; 2022 Dec; 113(12):4020-4029. PubMed ID: 36047968
[TBL] [Abstract][Full Text] [Related]
4. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
5. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor modified T-cells for cancer treatment.
Han X; Wang Y; Han WD
Chronic Dis Transl Med; 2018 Dec; 4(4):225-243. PubMed ID: 30603741
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.
Yu T; Lu Y; Fang J; Jiang X; Lu Y; Zheng J; Shang X; Shen H; Fu P
Cancer; 2024 Apr; 130(S8):1378-1391. PubMed ID: 37950749
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.
Beatty GL; O'Hara M
Pharmacol Ther; 2016 Oct; 166():30-9. PubMed ID: 27373504
[TBL] [Abstract][Full Text] [Related]
12. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
13. CAR-T cell therapy: a potential new strategy against prostate cancer.
Schepisi G; Cursano MC; Casadei C; Menna C; Altavilla A; Lolli C; Cerchione C; Paganelli G; Santini D; Tonini G; Martinelli G; De Giorgi U
J Immunother Cancer; 2019 Oct; 7(1):258. PubMed ID: 31619289
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Yu YD; Kim TJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
[TBL] [Abstract][Full Text] [Related]
15. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
17. Current challenges and emerging opportunities of CAR-T cell therapies.
Abreu TR; Fonseca NA; Gonçalves N; Moreira JN
J Control Release; 2020 Mar; 319():246-261. PubMed ID: 31899268
[TBL] [Abstract][Full Text] [Related]
18. Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy.
Jiang Y; Wen W; Yang F; Han D; Zhang W; Qin W
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205714
[TBL] [Abstract][Full Text] [Related]
19. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
Tang XY; Ding YS; Zhou T; Wang X; Yang Y
Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer.
Petty AJ; Heyman B; Yang Y
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32244520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]